Showing 6811-6820 of 8820 results for "".
- Patent Issued for Coya’s IL-2 Technologyhttps://practicaldermatology.com/news/patent-issued-for-coyas-il-2-technology/2474992/Coya Therapeutics has received a new U.S. patent for proprietary methods of producing a highly stable liquid formulation (aldesleukin) of recombinant human interleukin-2 (rhIL-2), according to a press release from the manufacturer.
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- FDA Panel Urges Removal of Talc from Consumer Products Due to Cancer Linkhttps://practicaldermatology.com/news/fda-panel-urges-removal-of-talc-from-consumer-products-due-to-cancer-link/2474873/A U.S. Food and Drug Administration (FDA) advisory panel has reinforced longstanding concerns over the carcinogenic potential of talc, urging the agency to restrict its use in foods, drugs, and cosmetics. Citing more than thre
- From WHA78: Skin Diseases Are a Global Public Health Priorityhttps://practicaldermatology.com/news/wha78-skin-diseases-are-a-global-public-health-priority/2474881/In what was termed a historic decision at the 78th World Health Assembly (WHA78) in Geneva, Member States unanimously adopted a resolution declaring skin diseases a global public health priority, according to a press statement.
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.
- Concerto Biosciences Completes Data Collection for Massive Skin Microbiome Interaction Projecthttps://practicaldermatology.com/news/concerto-biosciences-completes-data-collection-for-massive-skin-microbiome-interaction-project/2474768/Concerto Biosciences announced today that it has concluded the data acquisition phase of the Skin Universe Project (SUP), collecting over 33 million empirical data points in what it calls the largest known dataset of skin microbial interactions.
- Socioeconomic Disparities Tied to HS Diagnoseshttps://practicaldermatology.com/news/socioeconomic-disparities-tied-to-hs-diagnoses/2474703/Patients living in lower socioeconomic neighborhoods are more likely to be diagnosed with hidradenitis suppurativa (HS), according to a new cross-sectional analysis of data from the University of California San Francisco (UCSF) health system.
- GW Prior Certification Coordinator Offers Tips at ElderDermhttps://practicaldermatology.com/news/GW-Prior-Certification-Coordinator-Offers-Tips-ElderDerm/2474666/There are no shortcuts to getting dermatologic treatments authorized by Medicaid and insurance companies, George Washington University Department of Dermatology’s prior certification coordinator said at the ElderDerm 2025 Conference in Washington, DC. Effort and diligence are the keys when
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try